Aurora Cannabis Inc. announced its financial and operational results for the second quarter of fiscal 2025, reporting a total net revenue of $81.1 million, a 29% increase compared to $63.1 million in the prior year period. This growth was primarily fueled by a 41% rise in its global medical cannabis business, which contributed $61.3 million in net revenue and accounted for 76% of Aurora's consolidated net revenue.
The company's international revenue surged by 93% to $35 million, surpassing Canadian Medical revenue for the first time and comprising 57% of total global medical cannabis revenue. Adjusted gross margin before fair value adjustments improved to 54% from 51% year-over-year, with medical cannabis adjusted gross margin reaching 68%.
Aurora also reported a significant increase in adjusted EBITDA, which more than doubled to $10.1 million, up 210% from $3.3 million in the prior year quarter. Net income from continuing operations reached $1.7 million, compared to $0.4 million in the previous year. For fiscal Q3 2025, the company anticipates continued strong net revenue and adjusted gross margins in its global medical cannabis business, along with positive adjusted EBITDA and free cash flow.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.